In a landmark 72-week clinical trial, Eli Lilly's Zepbound achieved significantly greater weight loss compared to Novo Nordisk's Wegovy, marking a pivotal advancement in obesity pharmacotherapy.
Accropeutics’ oral TYK2/JAK1 inhibitor AC-201 has shown major efficacy in a Phase 2 trial for moderate-to-severe plaque psoriasis. The study indicates significant clinical improvements and a favorable safety profile, potentially reshaping autoimmune treatment standards.
